To block terminal complement C5 activation and reduce neuroinflammation, the long-acting humanized monoclonal antibody C5 complement inhibitor Ravulizumab-cwvz, which is approved d as a treatment for atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria, is now in a phase 3 randomized clinical trial for ALS (59, 60). This evidence concerns the gene C5 and atypical hemolytic-uremic syndrome.